Reduced lymphatic drainage might explain why skin reactions to sunlight, or photosensitivity, may lead to systemic immune reactions and overall disease flareups in people with systemic lupus erythematosis (SLE), a study suggests. Data showed that the flow of the skin’s lymphatic fluid — which sends cells and molecular signals to…
News
The U.S. Food and Drug Administration (FDA) has agreed to allow Kyverna Therapeutics to begin clinical testing of KYV-101, the company’s investigational cell therapy for lupus nephritis, a form of lupus that causes kidney damage. Kyverna submitted a request, in the form of an investigational new drug…
Kira Pharmaceuticals will test KP-104, an investigational therapy for a blood-clotting disorder associated with systemic lupus erythematosus (SLE), using KORU Medical Systems’ easy-to-use subcutaneous (under-the-skin) Freedom System infusion device. “We selected KORU Medical based on their track record of helping patients receive high-value therapeutics subcutaneously in the…
When given on top of standard therapy, zetomipzomib led to clinically significant reductions in urine protein levels, a marker of kidney impairment, in systemic lupus erythematosus (SLE) patients with active lupus nephritis, a severe form of lupus that causes kidney damage. That’s according to full data from the now…
To help dermatologists and nephrologists understand the importance of minority participation in lupus clinical trials and why such participation is lacking, the American College of Rheumatology (ACR) is announcing new continuing medical education (CME) offerings. Specifically, the new CME provides the specialists with information about racial disparities in…
A CAR T-cell therapy targeting disease-driving immune cells safely led to sustained disease remission for five people with systemic lupus erythematosus (SLE) who’d previously failed to respond to other treatments, a recent study reported. Treatment was also highly specific, preventing autoimmune activity, but didn’t impair general immune system…
Kyverna Therapeutics has submitted an investigational new drug (IND) application asking regulators for permission to begin clinical testing on KYV-101, an experimental cell therapy for lupus nephritis — a severe manifestation of lupus that causes kidney damage. The company is actively working with sites in the U.S. and…
Using clinical data collected over time, two machine learning computer models were found to accurately predict inpatient hospitalization due to systemic lupus erythematosus (SLE) — the most common form of lupus. One method was most accurate in using short-term clinical assessment data to foretell future hospitalizations, while the other…
The first participant has been dosed in a pivotal Phase 2/3 trial testing Biogen’s anti-inflammatory medication litifilimab (BIIB059) in people with cutaneous lupus erythematosus (CLE), the company announced. The study, called AMETHYST (NCT05531565), is recruiting adults with CLE, whose disease is active despite standard antimalarial treatment, at…
Equillium’s investigational antibody-based treatment, itolizumab (EQ001), led to significant reductions in urine protein levels — a marker of kidney dysfunction — in systemic lupus erythematosus (SLE) patients with active lupus nephritis, according to an interim analysis from the type B portion of the Phase 1b EQUALISE clinical trial.
Recent Posts
- Sometimes you just have to sit in the mess of lupus for a while
- Twin Phase 3 studies recruiting adults with lupus skin problems in US, Canada
- Understanding how menopause can affect our lupus symptoms
- Discovering a role the vagus nerve plays in chronic pain management
- Recognizing patterns is one of my greatest weapons against lupus flares